التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey |
| المؤلفون: |
Kostek, O., Hacioglu, M.B., Tastekin, D., Goksu, S.S., Alandag, C., Akagunduz, B., Karabulut, S. |
| بيانات النشر: |
Zerbinis Publications |
| سنة النشر: |
2020 |
| المجموعة: |
Pamukkale University Repository / Pamukkale Üniversitesi Açık Erişim Arşivi |
| مصطلحات موضوعية: |
Chemotherapy, Anti-VEGFtherapy, Disease controlrate, Hepatocellular carcinoma, Overallsurvival, Regorafenib, alpha fetoprotein, anthracycline, cisplatin, fluorouracil, gemcitabine, oxaliplatin, sorafenib, adult, advanced cancer, aged, alpha fetoprotein blood level, Article, cancer chemotherapy, cancer combination chemotherapy, cancer control, cancer patient, cancer survival, controlled study, drug efficacy, drug hypersensitivity, drug substitution, drug withdrawal, female, follow up |
| الوصف: |
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the second- or third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a second- or third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (pPFS=0.22 and pOS=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. © 2020 Zerbinis Publications. All rights reserved. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| تدمد: |
1107-0625 |
| العلاقة: |
Journal of B.U.ON.; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/37064Test; 25; 1897; 1903; 2-s2.0-85090483650; WOS:000573102800001 |
| الإتاحة: |
https://hdl.handle.net/11499/37064Test |
| حقوق: |
none |
| رقم الانضمام: |
edsbas.5D4A61D6 |
| قاعدة البيانات: |
BASE |
Full Text Finder